AR104121A1 - DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA - Google Patents
DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASAInfo
- Publication number
- AR104121A1 AR104121A1 ARP160100831A ARP160100831A AR104121A1 AR 104121 A1 AR104121 A1 AR 104121A1 AR P160100831 A ARP160100831 A AR P160100831A AR P160100831 A ARP160100831 A AR P160100831A AR 104121 A1 AR104121 A1 AR 104121A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- substituted
- aromatic
- ring
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos con actividad inhibidora selectiva de ACC2. Además, una composición farmacéutica que comprende el compuesto. Reivindicación 1: un compuesto caracterizado por la fórmula (1), o su sal farmacéuticamente aceptable, en donde R¹ heterociclilo aromático fusionado sustituido o no sustituido representado por la fórmula (2) en donde anillo B es anillo de 5 miembros; anillo C es anillo de 6 miembros; anillo A es carbociclo no aromático sustituido o no sustituido, heterociclo no aromático sustituido o no sustituido, carbociclo aromático sustituido o no sustituido o heterociclo aromático sustituido o no sustituido; -L¹- es -O-(CR⁶R⁷)ₘ-, -N(R⁸)-(CR⁶R⁷)ₘ- o -(CR⁶R⁷)ₘ-, en donde el enlace del lado izquierdo se une con R¹, el enlace del lado derecho se une con el anillo A; -L²- es -O-(CR⁶R⁷)ₙ-, -O-CR⁶=CR⁷-, -CR⁶=CR⁷- o -(CR⁶R⁷)ₙ-, en donde el enlace del lado izquierdo se une con el anillo A, el enlace del lado derecho se une con el grupo representado por la fórmula (3); cada R⁶ es, de modo independiente, hidrógeno, halógeno, ciano, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido o alquinilo sustituido o no sustituido; cada R⁷ es, de modo independiente, hidrógeno, halógeno, ciano, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido o alquinilo sustituido o no sustituido; R⁶ y R⁷ en el mismo átomo de carbono se pueden tomar junto con el átomo de carbono para formar el anillo; R⁸ es hidrógeno o alquilo sustituido o no sustituido; cada m es, de modo independiente, un número entero de 0, 1, 2 ó 3; cada n es, de modo independiente, un numero entero de 1, 2 ó 3; R² es alquilo sustituido o no sustituido; R³ es hidrógeno o alquilo sustituido o no sustituido; R⁴ es alquilcarbonilo sustituido o no sustituido, alquenilcarbonilo sustituido o no sustituido, alquinilcarbonilo sustituido o no sustituido, carbociclilcarbonilo no aromático sustituido o no sustituido, carbociclilcarbonilo aromático sustituido o no sustituido, heterociclilcarbonilo no aromático sustituido o no sustituido, heterociclilcarbonilo aromático sustituido o no sustituido, alquiloxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, carbocicliloxicarbonilo no aromático sustituido o no sustituido, carbocicliloxicarbonilo aromático sustituido o no sustituido, heterocicliloxicarbonilo no aromático sustituido o no sustituido, heterocicliloxicarbonilo aromático sustituido o no sustituido, carbamoilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido, alquenilsulfonilo sustituido o no sustituido, alquinilsulfonilo sustituido o no sustituido, carbociclilsulfonilo no aromático sustituido o no sustituido, carbociclilsulfonilo aromático sustituido o no sustituido, heterociclilsulfonilo no aromático sustituido o no sustituido, heterociclilsulfonilo aromático sustituido o no sustituido, o sulfamoilo sustituido o no sustituido; siempre que se excluyan los siguientes compuestos (i) a (ii), (i) los compuestos en los que R¹ es bencimidazolilo o imidazopiridilo sustituido con heterociclilalquilo aromático sustituido o no sustituido o heterociclilalquilo no aromático sustituido o no sustituido; y anillo A es piperidina; -L¹- es -NH-; -L²- es -CH₂-; y R⁴ es oxicarbonilo de ter-butilo, y (ii) el compuesto representado por la fórmulas (4), (5) y (6).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015068500A JP2016079168A (ja) | 2014-10-17 | 2015-03-30 | 9員縮合環誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104121A1 true AR104121A1 (es) | 2017-06-28 |
Family
ID=57014927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100831A AR104121A1 (es) | 2015-03-30 | 2016-03-29 | DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA |
Country Status (15)
Country | Link |
---|---|
US (2) | US10233156B2 (es) |
EP (1) | EP3279187B1 (es) |
JP (2) | JP2016079168A (es) |
KR (1) | KR102633911B1 (es) |
CN (1) | CN107428700B (es) |
AR (1) | AR104121A1 (es) |
AU (1) | AU2016240715B2 (es) |
CA (1) | CA2981419C (es) |
DK (1) | DK3279187T3 (es) |
ES (1) | ES2883265T3 (es) |
MX (1) | MX2017012396A (es) |
PL (1) | PL3279187T3 (es) |
RU (1) | RU2702637C2 (es) |
TW (1) | TWI719974B (es) |
WO (1) | WO2016159082A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | 9員縮合環誘導体 |
WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
JPWO2021235508A1 (es) | 2020-05-21 | 2021-11-25 | ||
US20230099203A1 (en) * | 2020-12-23 | 2023-03-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
CN113461611B (zh) * | 2021-07-08 | 2023-02-28 | 江苏法安德医药科技有限公司 | 一种咪喹莫特中间体的合成方法 |
CA3231153A1 (en) | 2021-09-08 | 2023-03-16 | Kosuke Takemoto | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2023090411A1 (ja) | 2021-11-19 | 2023-05-25 | 塩野義製薬株式会社 | 心疾患または骨格筋の疾患の治療用医薬 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58186941A (ja) * | 1982-04-26 | 1983-11-01 | Hitachi Ltd | 半導体製造装置 |
EP1087954A1 (en) * | 1998-06-15 | 2001-04-04 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6376494B1 (en) * | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
DE60033859T2 (de) | 1999-06-28 | 2007-11-08 | Janssen Pharmaceutica N.V. | Hemmer des Respiratorischen Syncytial Virus |
AU778218B2 (en) * | 1999-06-28 | 2004-11-25 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
US20060178400A1 (en) | 2004-11-05 | 2006-08-10 | Beutel Bruce A | Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8748627B2 (en) | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
EP1996567B1 (en) | 2006-02-15 | 2013-09-18 | AbbVie Inc. | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
WO2008079610A2 (en) | 2006-12-21 | 2008-07-03 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
WO2008126732A1 (ja) * | 2007-04-05 | 2008-10-23 | Daiichi Sankyo Company, Limited | 縮合二環式ヘテロアリール誘導体 |
DE102008030837A1 (de) | 2008-06-30 | 2010-01-14 | Siemens Aktiengesellschaft | Elektrochrome Formulierung, Herstellungsverfahren dazu und elektrochromes organisches Bauelement |
GB0812028D0 (en) | 2008-07-01 | 2008-08-06 | Syngenta Participations Ag | Fungicidal compositions |
EP2141140A1 (en) | 2008-07-03 | 2010-01-06 | L'AIR LIQUIDE, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Ceramic foams with gradient of porosity and gradient of catalytic active(s) phase(s) |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
US8501804B2 (en) | 2008-10-27 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
AU2009331179B2 (en) * | 2008-12-26 | 2014-09-18 | Sumitomo Pharma Co., Ltd. | Novel bicyclic heterocyclic compound |
WO2010111634A2 (en) * | 2009-03-26 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
EP2454254A2 (en) * | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
TW201206911A (en) * | 2010-04-27 | 2012-02-16 | Takeda Pharmaceutical | Bicyclic compound |
US8729102B2 (en) * | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
WO2012173099A1 (ja) * | 2011-06-14 | 2012-12-20 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有するアミノ誘導体 |
WO2013035827A1 (ja) | 2011-09-09 | 2013-03-14 | 塩野義製薬株式会社 | 新規オレフィン誘導体 |
WO2013142369A1 (en) * | 2012-03-23 | 2013-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pulmonary hypertension with leukotriene inhibitors |
WO2014061693A1 (ja) * | 2012-10-17 | 2014-04-24 | 塩野義製薬株式会社 | 新規非芳香族炭素環又は非芳香族複素環誘導体 |
JPWO2015056782A1 (ja) * | 2013-10-17 | 2017-03-09 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | 9員縮合環誘導体 |
-
2015
- 2015-03-30 JP JP2015068500A patent/JP2016079168A/ja active Pending
-
2016
- 2016-03-29 AR ARP160100831A patent/AR104121A1/es unknown
- 2016-03-30 ES ES16772963T patent/ES2883265T3/es active Active
- 2016-03-30 US US15/557,992 patent/US10233156B2/en active Active
- 2016-03-30 KR KR1020177030592A patent/KR102633911B1/ko active IP Right Grant
- 2016-03-30 JP JP2017510104A patent/JP6725177B2/ja active Active
- 2016-03-30 PL PL16772963T patent/PL3279187T3/pl unknown
- 2016-03-30 MX MX2017012396A patent/MX2017012396A/es unknown
- 2016-03-30 WO PCT/JP2016/060395 patent/WO2016159082A1/ja active Application Filing
- 2016-03-30 CA CA2981419A patent/CA2981419C/en active Active
- 2016-03-30 EP EP16772963.1A patent/EP3279187B1/en active Active
- 2016-03-30 AU AU2016240715A patent/AU2016240715B2/en active Active
- 2016-03-30 CN CN201680019885.7A patent/CN107428700B/zh active Active
- 2016-03-30 RU RU2017134668A patent/RU2702637C2/ru active
- 2016-03-30 TW TW105110183A patent/TWI719974B/zh active
- 2016-03-30 DK DK16772963.1T patent/DK3279187T3/da active
-
2019
- 2019-01-17 US US16/250,212 patent/US20190144396A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016079168A (ja) | 2016-05-16 |
ES2883265T3 (es) | 2021-12-07 |
CA2981419C (en) | 2023-08-08 |
KR102633911B1 (ko) | 2024-02-05 |
JPWO2016159082A1 (ja) | 2018-02-01 |
EP3279187B1 (en) | 2021-06-02 |
AU2016240715B2 (en) | 2020-10-08 |
CA2981419A1 (en) | 2016-10-06 |
JP6725177B2 (ja) | 2020-07-15 |
EP3279187A4 (en) | 2018-08-15 |
DK3279187T3 (da) | 2021-08-16 |
AU2016240715A1 (en) | 2017-09-28 |
PL3279187T3 (pl) | 2021-12-06 |
TW201643144A (zh) | 2016-12-16 |
TWI719974B (zh) | 2021-03-01 |
US10233156B2 (en) | 2019-03-19 |
CN107428700B (zh) | 2021-08-03 |
RU2702637C2 (ru) | 2019-10-09 |
KR20170131568A (ko) | 2017-11-29 |
MX2017012396A (es) | 2018-01-26 |
RU2017134668A (ru) | 2019-04-04 |
US20190144396A1 (en) | 2019-05-16 |
EP3279187A1 (en) | 2018-02-07 |
WO2016159082A1 (ja) | 2016-10-06 |
RU2017134668A3 (es) | 2019-05-24 |
CN107428700A (zh) | 2017-12-01 |
US20180079727A1 (en) | 2018-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104121A1 (es) | DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA | |
AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
NI201900029A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
AR086121A1 (es) | Derivados de oxazina y una composicion farmaceutica para inhibir bace1 que los contienen | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
PE20161476A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
AR109665A1 (es) | Mezclas herbicidas | |
AR100049A1 (es) | Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 | |
AR103266A1 (es) | Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados | |
AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
PE20201414A1 (es) | Derivado policiclico de piridona | |
AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
AR104528A1 (es) | Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
PE20191032A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos | |
AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
AR108109A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
AR101132A1 (es) | Derivados de pirazina agonistas del gpr40 para el tratamiento de la diabetes tipo ii | |
AR063805A1 (es) | Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas. | |
AR097435A1 (es) | 6-alquinilpiridinas |